File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Conference Paper: Low-dose aspirin and risk of gastric cancer development after Helicobacter pylori eradication: a territory-wide study with propensity score analysis

TitleLow-dose aspirin and risk of gastric cancer development after Helicobacter pylori eradication: a territory-wide study with propensity score analysis
Authors
Issue Date2018
PublisherHong Kong Academy of Medicine Press. The Journal's web site is located at http://www.hkmj.org/
Citation
The 23rd Medical Research Conference, Hong Kong, 20 January 2018. In Hong Kong Medical Journal, 2018, v. 24 n. 1, Suppl. 1, p. 17, abstract no. 14 How to Cite?
AbstractIntroduction: Individuals remain at risk of developing gastric cancer (GC) despite eradication of Helicobacter pylori (HP). Although aspirin was shown to be associated with a reduced GC risk in HP-infected subjects, it remains uncertain whether aspirin can reduce GC risk in HP-eradicated subjects. This study aimed to investigate the chemopreventive effect of aspirin in HP-eradicated subjects. Method: Subjects who had received clarithromycin-based triple therapy between 2003 and 2012 in all public hospitals in Hong Kong were identified. Those who failed HP therapy and developed GC within 12 months were excluded. The observation period started from the commencement of HP therapy (index date), and patients were censored at the end of study (December 2015), death, or GC diagnosis. Aspirin use was defined as once or more weekly use. Cox proportional hazard model with propensity score adjustment for covariates (including age, sex, comorbidities, and concurrent medications) was used to derive the hazard ratio (HR) and 95% confidence interval (CI) of GC with aspirin use. Results: Of the 63 605 eligible subjects (with a median follow-up of 7.6 years), 169 (0.27%) developed GC with an incidence rate of 3.5 per 10 000 person-years. Aspirin use was associated with a reduced GC risk (HR=0.30, 95% CI=0.15-0.61). Compared with the reference group (never use), more frequent aspirin use showed a significant decreasing trend of GC risk (Ptrend<0.001), with lowest risk observed among daily users (HR=0.21, 95% CI=0.05-0.94). Compared with never use, a longer duration of aspirin use was also associated with a lower risk of GC (<2 years: HR=0.92, 95% CI=0.51-1.64; 2-5 years: HR=0.27, 95% CI=0.09-0.80; ≥5 years: HR=0.07, 95% CI=0.02-0.31; Ptrend<0.001). Moreover, a lower risk was observed with a higher aspirin dose (<100 mg: HR=0.38, 95% CI=0.18-0.79; ≥100 mg: HR=0.15, 95% CI=0.03-0.65; Ptrend<0.001). Conclusion: Aspirin use was associated with a reduced GC risk in a dose-response manner in HP-eradicated subjects.
DescriptionOrganizer: Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong
Persistent Identifierhttp://hdl.handle.net/10722/276354
ISSN
2017 Impact Factor: 1.226
2015 SCImago Journal Rankings: 0.279

 

DC FieldValueLanguage
dc.contributor.authorCheung, KSM-
dc.contributor.authorChan, EWY-
dc.contributor.authorWong, AYS-
dc.contributor.authorChen, LJ-
dc.contributor.authorSeto, WKW-
dc.contributor.authorWong, ICK-
dc.contributor.authorLeung, WK-
dc.date.accessioned2019-09-10T03:01:27Z-
dc.date.available2019-09-10T03:01:27Z-
dc.date.issued2018-
dc.identifier.citationThe 23rd Medical Research Conference, Hong Kong, 20 January 2018. In Hong Kong Medical Journal, 2018, v. 24 n. 1, Suppl. 1, p. 17, abstract no. 14-
dc.identifier.issn1024-2708-
dc.identifier.urihttp://hdl.handle.net/10722/276354-
dc.descriptionOrganizer: Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong-
dc.description.abstractIntroduction: Individuals remain at risk of developing gastric cancer (GC) despite eradication of Helicobacter pylori (HP). Although aspirin was shown to be associated with a reduced GC risk in HP-infected subjects, it remains uncertain whether aspirin can reduce GC risk in HP-eradicated subjects. This study aimed to investigate the chemopreventive effect of aspirin in HP-eradicated subjects. Method: Subjects who had received clarithromycin-based triple therapy between 2003 and 2012 in all public hospitals in Hong Kong were identified. Those who failed HP therapy and developed GC within 12 months were excluded. The observation period started from the commencement of HP therapy (index date), and patients were censored at the end of study (December 2015), death, or GC diagnosis. Aspirin use was defined as once or more weekly use. Cox proportional hazard model with propensity score adjustment for covariates (including age, sex, comorbidities, and concurrent medications) was used to derive the hazard ratio (HR) and 95% confidence interval (CI) of GC with aspirin use. Results: Of the 63 605 eligible subjects (with a median follow-up of 7.6 years), 169 (0.27%) developed GC with an incidence rate of 3.5 per 10 000 person-years. Aspirin use was associated with a reduced GC risk (HR=0.30, 95% CI=0.15-0.61). Compared with the reference group (never use), more frequent aspirin use showed a significant decreasing trend of GC risk (Ptrend<0.001), with lowest risk observed among daily users (HR=0.21, 95% CI=0.05-0.94). Compared with never use, a longer duration of aspirin use was also associated with a lower risk of GC (<2 years: HR=0.92, 95% CI=0.51-1.64; 2-5 years: HR=0.27, 95% CI=0.09-0.80; ≥5 years: HR=0.07, 95% CI=0.02-0.31; Ptrend<0.001). Moreover, a lower risk was observed with a higher aspirin dose (<100 mg: HR=0.38, 95% CI=0.18-0.79; ≥100 mg: HR=0.15, 95% CI=0.03-0.65; Ptrend<0.001). Conclusion: Aspirin use was associated with a reduced GC risk in a dose-response manner in HP-eradicated subjects.-
dc.languageeng-
dc.publisherHong Kong Academy of Medicine Press. The Journal's web site is located at http://www.hkmj.org/-
dc.relation.ispartofHong Kong Medical Journal-
dc.relation.ispartofThe 23rd Medical Research Conference-
dc.rightsHong Kong Medical Journal. Copyright © Hong Kong Academy of Medicine Press.-
dc.titleLow-dose aspirin and risk of gastric cancer development after Helicobacter pylori eradication: a territory-wide study with propensity score analysis-
dc.typeConference_Paper-
dc.identifier.emailCheung, KSM: cks634@hku.hk-
dc.identifier.emailChan, EWY: ewchan@hku.hk-
dc.identifier.emailWong, AYS: angelwys@hku.hk-
dc.identifier.emailChen, LJ: equalclj@hku.hk-
dc.identifier.emailSeto, WKW: wkseto@hku.hk-
dc.identifier.emailWong, ICK: wongick@hku.hk-
dc.identifier.emailLeung, WK: waikleung@hku.hk-
dc.identifier.authorityCheung, KSM=rp02532-
dc.identifier.authorityChan, EWY=rp01587-
dc.identifier.authoritySeto, WKW=rp01659-
dc.identifier.authorityWong, ICK=rp01480-
dc.identifier.authorityLeung, WK=rp01479-
dc.identifier.hkuros302543-
dc.identifier.volume24-
dc.identifier.issue1, Suppl. 1-
dc.identifier.spage17, abstract no. 14-
dc.identifier.epage17, abstract no. 14-
dc.publisher.placeHong Kong-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats